Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2021-01-19 Capital/Financing Update
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PharmaTher has signed an exclusive worldwide license agreement for a patented ketamine formulation targeting mental health, neurological, and pain disorders. It discusses the details of the agreement, the product development plans, clinical trial intentions, and background information about the companies involved. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is not a transcript, audit report, or management discussion. It is a corporate announcement about a licensing agreement and product development, which fits best under Capital/Financing Update (CAP) as it relates to a significant licensing deal impacting the company's capital and business development activities. The document length is over 12,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2021-01-19 English
News release - English.pdf
Regulatory Filings
2021-01-13 English
News release - English.pdf
Regulatory Filings
2020-12-30 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PharmaTher has signed a non-binding letter of intent (LOI) to sell its psilocybin program to Revive Therapeutics. It details the terms of the LOI, the assets involved, and the strategic focus of both companies. There is no financial data, no regulatory filing format, no detailed financial report, and no mention of a shareholder meeting or voting results. The document is an announcement of a transaction (sale of intellectual property and program rights) rather than a merger or acquisition filing (which would be more formal and detailed). It is not a merger proxy or tender offer document. The content fits best under Capital/Financing Update (CAP) as it relates to a significant corporate transaction involving asset sale and strategic refocus. The document length is sufficient and contains substantive information about the transaction, not just a brief announcement or report publication notice.
2020-12-21 English
News release - English.pdf
Regulatory Filings
2020-12-16 English
News release - English.pdf
Regulatory Filings
2020-12-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.